

TITLE PAGE

Pharmacological and Toxicological Properties of the Potent Oral γ -Secretase Modulator BPN-15606

Authors

Steven L. Wagner, Kevin D. Rynearson, Steven K. Duddy, Can Zhang, Phuong D. Nguyen, Ann Becker, Uyen Vo, Deborah Masliah, Louise Monte, Justin B. Klee, Corinne M. Echmalian, Weiming Xia, Luisa Quinti, Graham Johnson, Jiunn H. Lin, Doo Y. Kim, William C. Mobley, Robert A. Rissman, and Rudolph E. Tanzi

Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0624, United States.

Affiliations

Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0624, United States (S.L.W., K.D.R., P.D.N., A.B., U.V., D.M., L.M., W.C.M., and R.A.R.); Integrated Nonclinical Development Solutions, Inc., 6111 Jackson Road, Ann Arbor, Michigan 48103 United States (S.K.D.); NuPharmAdvise, 3 Lakeside Drive, Sanbornton, New Hampshire 03269, United States (G.J.); Biopharm Consulting Partners, LLC, 2 Willet Drive, Ambler, Pennsylvania 19002, United States (J.H.L.); Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States (C.Z., J.B.K., C.M.E., W.X., L.Q., D.Y.K., and R.E.T.).

RUNNING TITLE PAGE

Pharmacological and Toxicological Properties of BPN-15606

Corresponding Author

Steven L. Wagner

slwagner@ucsd.edu

University of California, San Diego

Department of Neurosciences

9500 Gilman Drive MC 0624

La Jolla, CA 92093-0624

(858) 822-4281

Number of Text Pages: 39

Number of Tables: 0

Number of Figures: 11

Number of References: 33

Number of Words in the Abstract: 240

Number of Words in the Introduction: 738

Number of Words in the Discussion: 1,280

List of Abbreviations: A β , amyloid- β peptide; AD, Alzheimer's disease; AGSM, aminothiazole-bridged aromatic γ -secretase modulator; APP, amyloid precursor protein; AUC, area under the curve; BACE, beta-site amyloid precursor protein cleaving enzyme; BPN-3783, *N*-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[*c*]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine, BPN-15606, (*S*)-*N*-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; DAPT, *N*-[*N*-(3,5-Difluorophenacetyl)-*L*-alanyl]-*S*-phenylglycine *t*-butyl ester; DMSO, dimethyl

JPET #240861

sulfoxide; ELISA, enzyme-linked immunosorbent assay; FAD, familial Alzheimer's disease; GSI, γ -secretase inhibitor; GSM, γ -secretase modulator; HPLC, high performance liquid chromatography; LC, liquid chromatography; LLOQ, lower limit of quantification; MADLI-TOF, matrix-assisted laser desorption/ionization time of flight; MMSE, Mini-Mental State Examination; MRT, mean residence time; MS, mass spectrometry; NHP, non-human primate; PCE, polychromatic erythrocyte; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetic; RBC, red blood cell; TK, toxicokinetic.

Section Assignment: Neuropharmacology

ABSTRACT

Alzheimer's disease is characterized neuropathologically by an abundance of 1) neuritic plaques, which are primarily composed of a fibrillar 42 amino acid amyloid β peptide, as well as 2) neurofibrillary tangles composed of aggregates of hyperphosphorylated tau. Elevations in the concentrations of the A β 42 peptide in the brain, as a result of either increased production or decreased clearance are postulated to initiate and drive the AD pathological process. We initially introduced a novel class of bridged aromatics referred to as γ -secretase modulators that inhibited the production of the A β 42 peptide and to a lesser degree the A β 40 peptide while concomitantly increasing the production of the carboxyl-truncated A β 38 and A β 37 peptides. These modulators potently lower A β 42 levels without inhibiting the γ -secretase-mediated proteolysis of Notch or causing accumulation of carboxyl-terminal fragments of APP. Herein we report a large number of pharmacological studies and early assessment of toxicology characterizing a highly potent GSM, (*S*)-*N*-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine (BPN-15606). BPN-15606 displayed the ability to significantly lower A β 42 levels in the CNS of rats and mice at doses as low as 5-10 mg/kg, significantly reduce A β neuritic plaque load in an AD transgenic mouse model and significantly reduce levels of insoluble A β 42 and pThr181 tau in a 3D human neural cell culture model. Results from repeat-dose toxicity studies in rats and dose escalation/repeat dose toxicity studies in non-human primates have designated this GSM for 28-day IND-enabling GLP studies and positioned it as a candidate for human clinical trials.

Introduction

Alzheimer's disease (AD) is pathologically characterized by neuritic plaques and neurofibrillary tangles which result in a significant loss of neurons and synapses in areas of the brain important for cognition (Tanzi and Bertram, 2005). AD is an emerging health crisis that imposes a severe economic burden on those affected. In the absence of any disease-modifying treatments, the costs of AD may bankrupt our healthcare system in the next 3 decades (<http://www.Alz.Org>). Unfortunately, existing treatments are merely palliative, providing only temporary symptomatic benefit and do not affect the underlying progression of the disease.

A number of potential disease-modifying therapeutic approaches for AD either have previously failed or are currently just beginning to be tested clinically, yet none to date have been shown to impact disease progression (Sabbagh and Cummings, 2011; Qui, Kivipelto and von Strauss, 2009). Most treatment strategies currently being pursued have arisen from the genetic, biochemical and morphological data implicating the amyloid precursor protein (APP) and the A β products from proteolytic processing in the pathogenesis of AD. Consequentially, therapeutic strategies have focused on inhibiting the enzymes (secretases) responsible for A β production, thereby reducing the levels of all A β peptide species. While BACE inhibitors are currently under clinical scrutiny, γ -secretase inhibitors have not demonstrated efficacy and have shown significant side effects (Fleisher et al., 2008; Coric et al., 2012). In contrast, immunotherapy approaches which aim at clearing deposited A β peptides have recently shown potential against AD; however, this is only after years of failures (Miles et al., 2013; Salloway et al., 2014). Biogen recently reported results of a 52-week, 166-patient phase 1b clinical trial with an anti-A β human monoclonal antibody, aducanumab, which showed a statistically significant dose-dependent reduction of amyloid plaques as measured by florbetapir PET imaging, and statistically significant reduction in cognitive decline as measured by MMSE and CDR, relative to placebo, lending significant support to therapeutic strategies targeting plaque-associated A β peptides for the treatment of AD (Sevigny et al., 2016).

The neuritic plaques associated with AD are composed predominantly of A β 42 (Iwatsubo et al., 1994), and the most common biochemical phenotype observed for the more than 200 different familial AD (FAD)-linked mutations is an increased ratio of A β 42/A β 40 (Kumar-Singh et al., 2006). Moreover, a large body of data points to A β 42 as the most potentially pathogenic of this family of peptides (Tanzi and Bertram, 2005). Thus, selective attenuation of A β 42 relative to the shorter A β peptides (i.e., A β 40, A β 38 and A β 37) may prove to be a novel and efficacious avenue for interrupting AD progression (Wagner et al., 2013; Wagner et al., 2014; Kounnas et al., 2010). Since the A β peptides are produced as the result of the sequential proteolytic processing of the amyloid precursor protein (APP) by the aspartyl protease known as γ -secretase, small molecules capable of modulating the enzyme have been intensely pursued.

Our therapeutic approach is based on the amyloid cascade hypothesis (Hardy and Higgins, 1992) and utilizes a small molecule γ -secretase modulator to selectively attenuate the production of A β 42 while increasing the production of truncated A β species. While previous therapeutic approaches utilizing small molecules targeting the amyloid cascade hypothesis have been shown to be toxic (e.g. γ -secretase inhibitors such as semagacestat and avagacestat), γ -secretase modulation addresses the oligomeric-prone A β 42 peptide and does not interfere with overall enzyme function, thereby avoiding the inhibitor related side-effects. We view the γ -secretase modulation approach as superior to the use of vaccines and passive immunization which require invasive procedures and immune regulation. In addition, because γ -secretase modulators (GSMs) directly attenuate the level of A β 42 and to a lesser degree A β 40, while increasing levels of shorter A β peptides (A β 38 and A β 37) they may prove to be easier to test, evaluate and monitor clinically than compounds which inhibit the activities of either β -secretase.

Beyond slowing progression in symptomatic AD, an important additional therapeutic goal of disease modifying approaches is to prevent AD in high risk populations. This objective will be viewed as increasingly important if current immunotherapy and BACE inhibitor trials reinforce evidence that intervening after the development of abundant pathology severely limits efficacy. Intervening in AD for prevention or at stages of earliest symptoms requires many years of treatment, and a high priority is to

JPET #240861

identify drugs that are more affordable than antibodies, and that can be delivered orally, safely, and for decades before the onset of AD in people at risk by virtue of genetic predisposition, risk factors, or biomarker related to pre-symptomatic pathology.

Materials and Methods

Compounds. The novel GSM BPN-15606, (*S*)-*N*-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine, was synthesized at Albany Molecular Research Institute (AMRI) Albany, NY using the methods reported UCSD patent (Wagner et al., 2016) The GSI DAPT, *N*-[*N*-(3,5-Difluorophenacetyl)-*L*-alanyl]-*S*-phenylglycine t-butyl ester, was purchased from Sigma, St. Louis, MO.

A β ELISA Assays. All A β assays including the anti-A β immunoprecipitation/MALDI-TOF were carried out as described previously (Wagner et al., 2014).

Notch Assays. Notch assays were carried out as described previously (Wagner et al., 2014).

In Vitro ADMET. Kinetic Solubility: BPN-15606 (100 μ M) was introduced into aqueous PBS buffer pH 7.4 as a concentrated solution in DMSO for 1 hour. The concentration of dissolved compound was measured via UV/Vis absorbance against a calibration curve. Functional hERG: An automated patch-clamp technique was used to measure hERG conductance using HEK293 cells stably transfected with the human ERG gene. Inhibition is expressed as an IC₅₀ value determined from the percent inhibition versus test compound concentration curves using 5 concentrations of the test compound. Liver Microsomal Stability: BPN-15606 (1.0 μ M) was incubated with microsomes and cofactor regeneration system from human, rat, mouse, or dog for 30 min. LC/MS analysis was then used to measure the remaining compound. Microsomal Clearance: The test compound (1.0 μ M) was incubated with liver microsomes and cofactor regeneration system from human, rat, mouse, or dog. LC/MS analysis was then used to measure remaining compound at specified time points (0, 5, 10, 15, 30, and 45 minutes). MDR1 MDCK Permeability: Passive and active transport of BPN-15606 across a monolayer of MDR1-MDCK cells in two directions (apical to basolateral and reverse) was evaluated. Permeability and efflux ratio of the test compound were determined based on measurement of compound concentration in the receiving

compartment by LC/MS analysis. CYP Inhibition: The test compound was co-incubated with CYP-selective probe substrates and human liver microsomes. Inhibition of the CYPs was assessed by measuring formation of metabolites of probe substrates by LC/MS/MS analysis. Inhibition is expressed as an IC_{50} value determined from the percent inhibition versus test compound concentration curves using 8 concentrations of the test compound. CYP isoforms evaluated include 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 (two probe substrates are used for 3A4). CYP Induction: Test compound was incubated with cryopreserved plateable human hepatocytes from three individual donors. Upon incubation, CYP1A2, CYP2B6, and CYP3A4 enzyme activities are measured using specific probe substrates with LC/MS/MS detection to determine increase in enzyme activity compared to the vehicle control (fold induction). As positive controls, known CYP inducers are used. The acceptance criterion for assay performance (adequacy for detecting induction by BPN-15606) was a >2-fold induction of CYP isoforms in the positive controls. CEREP Profile: BPN-15606 (10 μ M) was incubated with a panel of 55 receptors (CEREP ExpressS, Redmond, WA) to determine potential off-target binding activity. Metabolite ID: Test compound (1 μ M) was incubated at 37 °C for 4 h with cryopreserved mouse, rat, dog, monkey, or human hepatocytes. Identification of metabolites' molecular weights and relative abundance of the specific metabolites was based on HPLC/MS/MS peak areas, and structural characterization of metabolites was accomplished by LC/MS/MS/Q-Trap.

Bioanalytical Method. Mouse, rat and non-human primate (NHP) plasma and brain extract calibration standards and quality control (QC) samples were prepared in untreated plasma or brain as follows: A primary stock solution of 2 mg/ml analyte [BPN-15606 or BPN-3783 (internal standard)] in DMSO was prepared, then dilutions performed to make spiking solutions of analyte in DMSO at various concentrations. One volume of spiking solution was added to 99 volumes of untreated plasma or brain extract to attain nominal concentrations of standards with a final non-plasma matrix concentration of 1.0%. Plasma Extraction Method: : To 50 μ l of sample in a 2 ml microfuge tube was added 0.9 ml acetonitrile containing 1600 ng/ml BPN-3783 (internal standard). Tubes were vortexed at maximum

speed on a plate vortexer 5 minutes, centrifuged 10 minutes at approximately 18,000 g, and 20 µl of the supernatant removed to a glass HPLC vial containing 880 µl of 85/15/0.1: water/acetonitrile/formic acid (v/v/v). Brain Extraction Method: Rat or mouse brain samples were stored frozen at -70 °C and thawed to room temperature, then homogenized in phosphate buffered saline (PBS) using a probe sonicator (15 sec at 50% maximal amplitude), using 4 ml PBS per 1 gram brain tissue. : To 50 µl of brain homogenate was added 0.3 ml acetonitrile containing 100 ng/ml BPN-3783, *N*-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[*c*]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine, (internal standard). Tubes were vortexed, centrifuged 10 minutes at approximately 18,000 g, and 75 µl of the supernatant removed to a glass HPLC vial containing 800 µl of 85/15/0.1: water/acetonitrile/formic acid (v/v/v). The vials were briefly vortexed prior to LC-MS/MS analysis.

The ultra-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method utilized a Shimadzu LC-20AD Pumps (Shimadzu, Columbia, MD), Leap Technologies CTC HTS PAL Autosampler (Leap Technologies, Durham, NC), a Phenomenex Luna C18(2), 50 X 2 mm, 5 µm column (Phenomenex, Torrance, CA) operated at 20°C and an AB Sciex QTrap 5500 mass spectrometer with multiple reaction monitoring (SCIEX, Concord, Ontario, Canada). The mobile phase consisted of (A) 0.1% formic acid in water (v/v) and (B) 0.1% formic acid in acetonitrile (v/v) delivered at 1.0 ml/min using a gradient elution mode. The initial elution condition was 2% B, which was maintained for 0.7 minute and increased to 95% B in 1 minute and maintained for 1.7 minute. It was then returned to 2% B in 0.2 minute and maintained for 1.5 minute. The MS-MS analysis was performed using electrospray ionization, positive ion mode with the source temperature at 600 °C. The ion spray voltage was 3500V and the collision energy was 40 eV for BPN-15606 and 45 eV for BPN-3783 (internal standard). Mass to charge ratios of 419.2 (precursor ion) and 297.1 (product ion) were used for multiple reaction monitoring of BMS-15606. Mass to charge ratios of 422.1 (precursor ion) and 214.05 (product ion) were used for multiple reaction monitoring of BPN-3783. Integration and quantitation was by the Analyst software.

The lower limit of quantitation (LLOQ) was 1.0 ng/ml. The range of the plasma standard calibration curve (LLOQ to upper limit of quantitation (ULOQ) was 10.0 to 10,000 ng/ml. The coefficient of determination (r^2) was ≥ 0.999 in the sample analysis.

Animal Studies. All animal experiments were conducted following The National Institutes of Health guidelines and were in compliance with the policies of The University of California San Diego Institutional Animal Care and Use Committee (IACUC) and the SRI International IACUC.

PK in Mouse and Rat. Male CD-1 mice and male Sprague Dawley rats were administered a single dose of BPN-15606 by intravenous (iv) or oral gavage (po) dose routes to assess oral bioavailability. Mice and rats received BPN-15606 as a single iv dose at 1 mg/kg (n=5) or a single po dose at 5 mg/kg (n=5). Blood was collected from mice and rats at 5 (iv only), 15 and 30 minutes, and 1, 2, 4, 8 and 12 hours post-dose for processing to plasma. For mice, brains were collected from both dose groups (iv and po) at 1, 4, 8 and 12 hours post-dose. For rats, brains were collected from those same animals at the 12 hour time point only. Plasma, CSF and brains were collected at 1 hour post-dose from another group of rats treated with BPN-15606 at 1 mg/kg (iv). All samples were analyzed by LC-MS/MS for BPN-15606 levels using a bioanalytical method that had an LLOQ of 1 ng/ml in plasma and CSF and 5 ng/g in brain tissue. Clinical observations were performed immediately post-dose. All animals appeared normal throughout the study.

PK Non-human Primates. Male non-naïve Cynomolgus monkeys (non-human primates; NHP) were administered BPN-15606 as a single nasogastric (po; 2 mg/kg) or intravenous (iv; 1 mg/kg) dose to assess oral bioavailability. Whole blood samples were collected at specific time points and processed to plasma. Study in-life was conducted at Charles River Laboratories (Reno, NV). Pharmacokinetic (PK) plasma samples were shipped to SRI International for determination of drug concentrations. Samples were analyzed at SRI International using the bioanalytical method described above, validated for NHP plasma, and the LLOQ was 1 ng/ml.

PK Analysis. Data were subjected to non-compartmental analysis using WinNonlin® Phoenix Model 200 (for extravascular administration) or Model 201 (for iv bolus administration) and the sparse sampling feature; a uniform weighting factor was applied to each data set. Tmax and Cmax values were determined directly from the data. AUClast values were calculated using the log/linear trapezoidal (iv dose) or linear up/log down trapezoidal (po dose). Values were calculated using the plasma data from composite groups. The dose administered was input to the program as mg/kg, and as a result no additional corrections for individual body weights of the animals were necessary. The following parameters and constants were determined for the iv and po groups: observed maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), area under the plasma concentration-time curve to the last time point (AUClast), area under the plasma concentration-time curve extrapolated to infinity (AUCinf), terminal phase elimination half-life ($t_{1/2}$), and mean residence time to the last time point (MRTlast). The volume of distribution at steady state (Vss) and clearance (Cl) were calculated using the iv group data. Bioavailability (F) after oral administration was calculated using the AUClast values for both the iv and po groups.

Repeat Dose Efficacy Studies in Mice and Rats. Male C57BL/6J mice (n = 10/dose level) and male Sprague Dawley rats (n = 14/dose level) were administered either vehicle (80% PEG 400 v/v; 20% sterile water v/v and 0.1% Tween-20 v/v) or BPN-15606 (10, 25 and 50 mg/kg) once daily (qd) po by oral gavage for 7 consecutive days (mice) or 5, 25 and 50 mg/kg qd po by oral gavage for 9 consecutive days (rats). Clinical observations were performed immediately following dosing on each day and all animals appeared normal throughout the study. Animals were sacrificed 4 h following the dosing on day 7 of the 7-day oral treatment course (mice) and on day 9 of the 9-day oral treatment course (rats). Plasma and brain extracts were prepared (mice and rats) and CSF was aspirated from the cisterna magnum with minimal to no blood contamination (rats only) and tissues were frozen at -70°C. A β peptides were quantitated in brain extracts and plasma (mice) or CSF and plasma (rats) as described previously using

Meso Scale multiplex kits and the Meso Scale Sector Imager 6000 (Kounnas et al., 2010). Statistical analysis was performed using Graphpad Prism software and results are expressed as mean \pm SEM. ANOVA was used to detect a significant effect. Drug levels of BPN-15606 were measured in plasma and brain extracts using the bioanalytical methods detailed above.

Acute Single Dose Pharmacodynamics in Mice. Male C57BL/6J mice (n=5 per group) were administered a single dose of either vehicle (80% PEG 400 v/v; 20% sterile water v/v and 0.1% Tween-20 v/v) or BPN-15606 (25 mg/kg) by oral gavage (po) and sacrificed at 0.5, 1, 2, 4, 8, 12 and 24 h following the dosing. Plasma and brain extracts were prepared and A β peptides were quantitated as described previously (Kounnas et al., 2010). Statistical analysis was performed as described above for the repeat dosing studies..

Chronic Repeat Dose Efficacy in Transgenic Mice. Thirty-five female double transgenic mice, model PSAPP (Jankowsky et al., 2004), purchased from Jackson Laboratory (B6.C3-Tg [APP^{swe}, PSEN1^{dE9}] 85Dbo/Mmjax, stock no. 0034829) and then bred in-house, were used in the study at 90 days of age. The mice were housed in a temperature-controlled room at a constant 22 °C in a 12:12-h light/dark cycle (lights off at 18:00), with food and water available ad libitum. Age-matched mice were housed by treatment group in groups of 2-4 per cage. All experimental procedures were reviewed and approved by IACUC at UC San Diego. Subjects were randomly assigned to either the drug group (BPN-15606) or vehicle, with individual groups ranging from 9-10 mice. Mice were treated for six months with BPN-15606 at a dose of 10 mg/kg/d. For the drug administration, BPN-15606 was milled into standard rodent chow, processed by Research Diets, Inc. (New Brunswick, NJ). All animals were weighed three times weekly to assess any adverse effects on normal weight gain during the six-month treatment period. Food consumption was determined by weighing the metal cage, including the chow, to the nearest 0.1 g.

Thioflavin S Staining and Amyloid Fibril Quantification: To determine A β fibril plaque load, floating coronal sections from AD and wildtype mice, n = 4 for each group, were washed in miliQ water

and mounted on Fisherbrand Superfrost Plus microscope slides, before being processed for 1% (w/v) Thioflavin S staining. All images were taken with Leica fluorescence microscope at 5X and with the same exposure across all images. The percent plaque within specified areas of a series of hippocampal and frontal cortex sections was quantified using ImageJ software from NIH. Images were converted to 8-bit gray scale, area of interest was traced and determined. Brightness and B/W threshold were adjusted appropriately and consistently across all images. The area of plaque particles within the area of interest was obtained and the percent plaque was calculated. The series of sections of each animal was averaged and grouped accordingly prior to statistical analysis. The number of series of section per animal ranged from 3-14 sections.

3D Human Neural Cell Culture Model of AD. Cells and drug treatments: HReN-mGAP AD ReN cells expression APP^{Swedish/London} and Presenilin 1^{ΔE9} were previously described (Choi et al., 2014). The HReN-mGAP AD ReN cells were 3D-differentiated for 7 weeks as previously described (Kim et al., 2015). The cultures were then harvested and analyzed for the soluble (conditioned media) and insoluble Aβ_{40/42/38} and p-tau/tau levels, using MSD Mesoscale electrochemiluminescence system. BPN-15606 (70 nM) and the same volume of DMSO controls were treated in the last 4-weeks. The potential toxicity of the drugs was monitored by CytoTox-ONE™ (LDH) assay after 1 week of the treatments. At the end of the treatments, the soluble (media) and the insoluble fractions (5M GuHCl-soluble extracts) were collected and analyzed for Aβ₃₈, Aβ₄₀ and Aβ₄₂ with MSD ELISA (V-Plex 6E10 Aβ_{40/42/38} kit). The custom made plates were used for detecting total tau (BT2, ThermoFisher Scientific) and pThr181 tau (At270, ThermoFisher). The insoluble fraction was dissolved in 5M GuHCl and pThr181 tau, total tau, Aβ₄₀, Aβ₄₂ and Aβ₃₈ concentrations were determined by MSD ELISA. The levels of the control protein Tuj1 were determined by dot-blot analysis in the GuHCl lysates (data not shown).

Repeat-Dose Toxicity and Micronucleus Evaluation of BPN-15606 in Rats. The objectives of this toxicity study were to determine maximum tolerated dose (MTD), characterize the potential toxicity, and

calculate toxicokinetic (TK) parameters of BPN-15606 in adult male Sprague Dawley rats (8-10 weeks of age) following daily oral gavage (po) dose administration for 7 consecutive days, and to evaluate its potential to damage chromosomes or cause mitotic spindle abnormalities *in vivo* as measured by the incidence of micronucleus formation in RNA-containing erythrocytes (bone marrow micronucleus assay). An overview of the study design is presented in Supplemental Table 8. Male rats were administered BPN-15606 by oral gavage for 7 consecutive days at 30, 100 or 300 mg/kg (Groups 2, 3 and 4). A control group (Group 1) was given vehicle, 15% Labrasol/85% sterile water, at an equivalent dose volume (10 ml/kg). A 375 mg/kg dose (Group 5) was included for determination of Day 1 plasma drug levels. Clinical observations were recorded twice daily.

All rats in Groups 1, 2, and 3 (0, 30 and 100 mg/kg, respectively) survived until their scheduled Day 8 sacrifice, and all tissues specified for histologic evaluation were collected. None of the Group 4 (300 mg/kg) animals survived the 7-day dosing period: 3 were sacrificed in moribund condition and 2 were found dead. Necropsy examinations were performed on all rats, but for Group 4 animals, tissues for histopathologic examination were collected only from those rats that were sacrificed in moribund condition. Histopathology assessment was conducted on all tissues collected from all animals in Groups 1 and 3, and all tissues collected from Group 4 animals euthanized moribund. From Group 2 rats, the following tissues were examined histopathologically: duodenum; jejunum; ileum; liver; lung; pancreas; spleen; stomach; and, thymus, which were evaluated based on findings at the higher dose levels. When present, grossly altered tissues were examined histopathologically from all Groups 1, 2, and 3 rats, and from moribund sacrifice Group 4 rats. Microscopic data were recorded and a four-step grading system (minimal, mild, moderate and marked) was used to define gradable changes. Terminology for data capture was consistent with International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) as promulgated by the Society of Toxicologic Pathology.

The micronucleus component of this study was performed to evaluate the ability of BPN-15606 to induce chromosomal damage in bone marrow of male Sprague-Dawley rats. Rats (n = 5/Group) were scheduled to receive single daily doses of BPN-15606 for 7 days at 30, 100, and 300 mg/kg/day (Groups

2, 3 and 4, respectively), with euthanasia scheduled 24 hours after the final dose. Animals receiving 300 mg/kg/day were sacrificed in moribund condition on Days 3 or 4 due to excessive toxicity, and micronucleus formation was not evaluated; all other treated animals survived to necropsy. Bone marrow samples collected from the low and mid dose groups (30 and 100 mg/kg) were evaluated for cytotoxicity and for micronucleus formation (see Supplemental Table 8). Three bone marrow smear slides were prepared per animal and fixed in absolute methanol. Positive control (cyclophosphamide) slides generated in a separate GLP-compliant study were stained and included for scoring. Two slides per animal were stained with acridine orange, coded, and evaluated (blind) using epifluorescence microscopy. Under these conditions, the cytoplasm of polychromatic erythrocytes (PCE) exhibits orange fluorescence, and the DNA of any micronuclei present exhibits yellow fluorescence. The criteria employed for identifying and quantitating micronuclei are those described by Schmid (Schmid, 1975). Two principal parameters were determined: (1) the number of PCE among 200 total RBC per animal (PCE/RBC ratio), which provides an index of bone marrow cytotoxicity, and (2) the number of micronucleated RNA-positive PCE among a total of 2000 PCE per animal, which provides an index of chromosomal damage.

Dose Escalation/Seven-Day Oral Gavage Toxicity and Toxicokinetics Study of BPN-15606 in NHP.

The objectives of this study were to determine the maximum tolerated single dose (MTD) of BPN-15606, characterize potential toxicity, and calculate toxicokinetic (TK) parameters of BPN-15606 in adult male and female cynomolgus macaques following daily oral gavage (po) dose administration at a near-MTD dose of BPN-15606 for 7 consecutive days. In the dose escalation phase to establish the MTD (Phase A), male and female cynomolgus macaques ($n = 2/\text{sex}$) were administered single doses of BPN-15606 at 3, 10, 30, 100, and 300 mg/kg, with 2 to 4 days between each dose escalation (Fig. 10). Clinical signs were limited to emesis in the 100 and 300 mg/kg groups. There were no apparent changes in the clinical pathology parameters after single dose administration. The plasma drug concentrations at the approximate T_{max} increased in a dose dependent manner. Based on these results, 300 mg/kg was selected for evaluation in the 7-day repeat dose phase of the study (Phase B). Comprehensive evaluation of clinical

JPET #240861

pathology parameters (clinical chemistry, hematology), gross pathology, and histopathologic parameters was carried out at SRI (Palo Alto, CA) according to their standardized protocols. Tissues examined histopathologically included: liver, lung, stomach, duodenum, colon, spleen, pancreas, thymus, heart, brain and kidney.

Results

In Vitro Effects of BPN-15606 on γ -Secretase Activity. During the past 4 years we have synthesized and characterized over 600 novel GSMs encompassing four closely related scaffolds. Rigorous *in vitro* pharmacokinetic, pharmacodynamics and toxicological evaluation of these compounds led to the discovery of BPN-15606 (Fig. 1), which exhibits excellent drug-like properties. Based on the balance of data summarized in Supplemental Table 1, BPN-15606 progressed into nonclinical development. BPN-15606 is a GSM and as such, binds to an allosteric site within the γ -secretase enzymatic complex and reduces the amount of secreted A β 42 (Crump et al., 2013). *In vitro*, BPN-15606 exhibits an IC₅₀ value of 7 nM for attenuating the production of A β 42 by human SHSY5Y neuroblastoma cells stably overexpressing human APP751 wild-type as measured by ELISA (Fig. 2). Importantly, treatment with BPN-15606 does not affect Notch cleavage at doses as high as 25 μ M as shown in Fig. 3. Proteolysis of Notch by γ -secretase is necessary for proper cellular differentiation, and inhibition of Notch cleavage by γ -secretase inhibitors was previously associated with significant side effects (Doody et al., 2013). Supplemental Tables 1 and 2 summarize the *in vitro* ADMET properties of BPN-15606 (Supplemental Table 1) as well as the *in vitro* metabolites identified in hepatocyte cultures from five species (Supplemental Table 2). Collectively, these studies established that BPN-15605 has an acceptable *in vitro* ADMET profile to enable *in vivo* studies and that there were no uniquely human metabolites identified.

This GSM mechanism is illustrated in the anti-A β IP/MALDI-TOF experiment depicted in Fig. 3 which shows that neuronal cells treated overnight with 100 nM of BPN-15606 completely eliminate the peak corresponding to A β 42 and significantly reduce the A β 40 peak while the size of the A β 38 and A β 37 peaks are significantly increased. This GSM mechanism appears to be free of the known toxicities associated with inhibiting the γ -secretase enzymatic complex which is responsible for cleaving a large number of type 1 membrane proteins (Wakabayashi and De Strooper, 2008; Haapasalo and Kovacs, 2011).

Pharmacokinetics of BPN-15606 in Mice, Rats and NHP. Plasma concentrations of BPN-15606 measured in CD-1 mice and Sprague Dawley rats were used to determine pharmacokinetic (PK) parameters, which are summarized in Supplemental Tables 3 and 4. Both species showed bioavailability (F) of greater than 60%. In male non-naïve Cynomolgus monkeys (NHPs) plasma concentrations of BPN-15606 were readily quantitated, facilitating assessment of plasma PK parameters which are summarized in Supplemental Table 5. These data indicate bioavailability is significantly less favorable relative to rodents (F of 30.8% compared to mice and rats, which were both greater than 60%).

Biochemical Efficacy of BPN-15606 in Mice and Rats. BPN-15606 was repeatedly administered once daily by oral gavage to both mice (7-days) and rats (9-days) at various doses (see Fig. 5).. BPN-15606 showed excellent dose-dependent efficacy in both plasma and brain (mice) and plasma and CSF (rats) on lowering of A β 42 and A β 40 levels.. Importantly, BPN-15606 also showed dose-dependent exposures in these two studies (see Supplemental Tables 6 and 7 for plasma drug levels in the same animals where the A β peptide levels were measured). The data in Fig. 5 also demonstrate excellent pharmacodynamic concordance between plasma and brain (mouse) and plasma and CSF (rat) for the ability of BPN-15606 to lower A β 42 and A β 40 levels in a dose-dependent manner. The effects of BPN-15606 were consistently greater in lowering plasma A β levels than either brain or CSF A β levels probably due to the higher exposures of free drug in plasma (see Supplemental Tables 6 and 7) as well the shorter half-life of plasma A β peptides compared to the central nervous system turnover of A β peptides (Cirrito et al., 2003). Time course studies were also carried out in C57BL/6 mice following a single oral dose of BPN-15606 (25 mg/kg). As expected at this dose (25 mg/kg), BPN-15606 showed a robust effect on both brain and plasma A β 42 and A β 40 levels which began approximately 30-60 min following the single dose administration and lasted for \geq 24 hours.

Efficacy of BPN-15606 in PSAPP Transgenic Mice Following Chronic Treatment. To determine whether chronic BPN-15606 therapy could ameliorate A β plaque accumulation, the percentage of area occupied by A β plaques in PSAPP mice was quantified after 6 months of treatment with BPN-15606 at an estimated daily dose of 10 mg/kg. It is well established that the specific transgenic mouse model used in this study (PSAPP) develops A β deposits by 2-3 months of age with reliable onset of A β neuritic plaques at six months of age (Jankowsky et al., 2004; Zhang et al., 2016). Using Thioflavin S stained coronal sections and densitometry, we confirmed that vehicle-treated female PSAPP mice at nine months of age demonstrated significant accumulation of A β plaques (Fig. 7B) when compared to age matched BPN-15606 treated PSAPP mice (Fig. 7C) and non-transgenic wild-type littermates (Fig. 7A). As regards to the quantitative analysis of treatment impact, densitometric measurements using NIH ImageJ software showed that chronic treatment with BPN-15606 significantly reduced accumulation of A β neuritic plaques in both the hippocampus and cortex (Fig. 7D and E). Necropsies were carried out at the end of the study with no significant adverse findings in either the vehicle or BPN-15606 treatment groups (data not shown).

Efficacy of BPN-15606 on Soluble and Insoluble A β 42, A β 40, A β 38, Total Tau and p-Thr181 Tau in 3D Human Neural Cell Cultures. BPN-15606 treatment (70 nM) dramatically decreased soluble levels of A β 40, A β 42, and A β 42/40 ratio while increasing A β 38 levels in the 3D human neural cell culture model of AD (Fig. 8A). BPN-15606 treatment also decreased insoluble (5M GuHCl-soluble extracts) A β 40 and A β 42 levels (Fig. 8B). More importantly, BPN-15606 treatment decreased insoluble pThr181 tau and total tau levels (Fig. 8C), suggesting that BPN-15606 treatment reduces p-tau pathology as well as A β accumulation. This result is not unexpected since other A β 42 lowering compounds (e.g. BACE inhibitors) have also been shown to impact p-tau pathology in this 3D human culture system (Choi et al., 2014). Interestingly, A β 38 was not detected in insoluble fractions, suggesting that the A β 38 species does not aggregate with A β 40 or A β 42 at least not in 3D human neural cell culture conditions.

Repeat-Dose Toxicity and Micronucleus Evaluation of BPN-15606 in Rats. Animals in the vehicle and 30 mg/kg BPN-15606 treated groups appeared normal throughout the treatment period. Several clinical observations were noted in the 100 and 300 mg/kg dose groups during the study, including hunched posture, hypoactivity, and discharge from nostrils, eyes and/or mouth. All animals in the 300 mg/kg dose group were either found dead or sacrificed in moribund condition on Day 3 or 4, indicating this dose exceeded the MTD. One animal in the 100 mg/kg toxicokinetic evaluation group died on Day 4. This animal died within approximately one minute of administration of test article, and blood was present in the thoracic cavity on gross necropsy evaluation. Thus, the death was likely due to procedural (gavage) error and not related to the BPN-15606. The primary hematology findings consisted of statistically significant but small increases in RBC (\uparrow 10.5%), hemoglobin (\uparrow 10.9%), and MCHC (\uparrow 10.7%), and decrease in MCH (\downarrow 6.9%) that were present in rats administered 100 mg/kg (Group 3). The absolute number and percent of reticulocytes were markedly decreased in the 100 mg/kg dose group, falling to about 20% of the control values after 7 days of treatment. Clinical chemistry changes were limited to small reductions in serum protein and albumin concentrations at 100 mg/kg (Group 3), elevated serum cholesterol in both Groups 2 (30 mg/kg) and 3, and lower triglycerides in Group 3 compared to the controls; these changes were not toxicologically significant. Histopathologic lesions attributed directly (duodenum, stomach, liver) or indirectly (lung, pancreas, thymus) to BPN-15606 were limited to the mid- (100 mg/kg) and high-dose (300 mg/kg) groups, and were absent at the low dose (30 mg/kg). The duodenum displayed mucosal inflammation, edema, necrosis, erosion, ulceration, and/or serosal inflammation. Histopathologic changes in the stomach included: non-glandular epithelial hyperplasia, hyperkeratosis, erosion, and ulceration; non-glandular submucosal fibrosis, edema, increased inflammation, and fibrosis; and/or, serosal inflammation. Hepatocyte basophilia, hypertrophy, and lipidosis was present in liver at the high (lethal) dose. Other microscopic observations in lung, pancreas and thymus were secondary to malaise associated with gastrointestinal lesions.

BPN-15606 did not induce micronuclei in the bone marrow of rats following 7 days of treatment at 30 or 100 mg/kg, indicating it does not appear to have clastogenic potential in vivo.

BPN-15606 absorption was prolonged, with T_{max} for individual animals occurring at 4 to 24 hr, depending on dose. The apparently continuous absorption of BPN-15606 from the gastrointestinal tract is likely the result of slow dissolution rate caused by poor aqueous solubility. The mean T_{max} was 13.3 hr (Day 1) or 6.7 hr (Day 7) in the 30 mg/kg dose group. The time to the peak plasma drug level was later on Day 1 in the 100 and 300 dose groups, with a mean value of 18.7 hr. Mean values for C_{max} and AUC_{last} on Day 1 increased with dose, although the increases were not proportional to dose from 100 to 300 mg/kg. The less than dose-proportional increase in systemic exposure (C_{max} and AUC) of BPN-15606 is also likely due to poor solubility. Day 7 pre-dose samples all contained a significant concentration of BPN-15606, which resulted in exposure parameters that were markedly higher on Day 7 than Day 1 (see Fig. 9). The MRT_{last} values ranged from 9.1 hr for the 30 mg/kg group on Day 1 to 13.6 hr for the 100 mg/kg group on Day 1. Thus, significant drug accumulation of BPN-15606 was observed in rats following once daily dosing for 7 days.

In summary, BPN-15606-related mortalities occurred in the 300 mg/kg group. Adverse effects on the erythroid system are consistent with responses to acute hemorrhaging, which is supported by histopathologic findings of necrosis, erosion, and ulceration in stomach and duodenum. The liver was also identified as a target organ, based on microscopic evidence of basophilia, hypertrophy, and lipidosis in liver of rats treated with 300 mg/kg. There was no significant suppression of polychromatic erythrocytes (PCE) among red blood cells (RBC) in bone marrow, and no statistically significant increase in the frequency of micronucleated PCE was seen at any dose level evaluated compared to vehicle controls. No toxicologically significant effects were observed in the 30 mg/kg dose group. The No-Observed-Effect Level (NOEL) of BPN-15606 is thus 30 mg/kg/day when given po daily for 7 consecutive days to rats, and the maximum tolerated dose (MTD) of BPN-15606 is considered to be approximately 100 mg/kg/day.

Dose Escalation/Seven-Day Oral Gavage Toxicity and Toxicokinetics Study of BPN-15606 in NHP.

In the dose escalation phase, male and female cynomolgus macaques were administered single doses of

BPN-15606 by the oral route at doses of 3, 10, 30, 100, and 300 mg/kg, with 2 to 4 days between each dose escalation (Fig. 10). Clinical signs were limited to emesis in the 100 and 300 mg/kg groups. There were no apparent changes in the clinical pathology parameters after single dose administration for any of the doses evaluated. The plasma drug concentrations at the approximate T_{max} increased in a dose dependent manner. Based on these results, 300 mg/kg was selected for the 7-day repeat dose phase of the study (Phase B). Daily oral administration of 300 mg/kg BPN-15606 resulted in clinical signs of emesis, reduced appetite, and reduced stool. Weight loss occurred with repeat dose administration which ranged from 3.2% to 10.5%. Based on the adverse clinical signs and weight loss the study was terminated one day early (after 6-days of dosing).

Toxicokinetic analysis of plasma drug levels identified a T_{max} of 2 to 4 hr and mean plasma half-life ($t_{1/2}$) was 8.7 hr and 10.2 hr, on Days 1 and 6, respectively. Daily administration of BPN-15606 led to accumulation and based on the AUClast, exposure to BPN-15606 was about 1.7 fold higher on Day 6 than on Day 1 (Fig. 11).

Histopathological findings that are considered to be related to repeated dose administration of BPN-15606 (300 mg/kg) were present in kidney, and possibly liver. Renal findings included mild to moderate proximal tubular necrosis, casts and dilation with cortical and medullary subacute inflammation in two male monkeys and one of two female monkeys. Hepatic findings were less convincing but included minimal sinusoidal leukocytosis in two male monkeys, and moderate focal fatty infiltration in one female monkey. These histopathological changes are consistent with the increased creatinine (renal effects) and increased total bilirubin (hepatic effects) that were noted in clinical chemistry analysis (data not shown). Adverse effects on the kidneys may be responsible for the decreased platelets and reticulocytes due to lower erythropoietin (EPO) levels from kidneys and subsequent reduction in hematopoiesis. Changes in serum triglycerides and cholesterol are likely to be related to the observed weight loss, but may also be a direct effect of BPN-15606.

In summary, administration of a single dose of BPN-15606 to cynomolgus monkeys at doses of 3, 10, 30, 100, and 300 mg/kg resulted in emesis only at the 100 and 300 mg/kg dose levels. There were no

other adverse findings noted during the single dose administration phase. Based on these data the maximum tolerated dose (MTD) after a single dose administration was estimated to be ≥ 300 mg/kg, and the no effect level (NOEL) after a single dose was 30 mg/kg. Administration of 300 mg/kg BPN-15606 by oral gavage daily for 6 consecutive days to cynomolgus monkeys was associated with weight loss and adverse cortical and medullary renal findings, which were supported by changes in clinical chemistry parameters. Based on these observations and under the conditions of this study, the MTD is estimated to be significantly below 300 mg/kg/day. An NOAEL could not be determined for the repeat dose range finding phase (Phase B).

Discussion

We have shown *in vivo* PK/PD properties with BPN-15606, have characterized key toxicological properties of the molecule, and have demonstrated significant dose-dependent biochemical efficacy (lowering of CSF and brain A β 42 levels by ~40% at doses as low as 5-10 mg/kg in rats and mice, respectively; Fig. 5) and dose proportional exposures from 5-50 mg/kg in both species (Supplemental Tables 6 and 7). At higher doses (25 mg/kg) BPN-15606 can almost totally eliminate (~70-75% lowering) A β 42 levels in both brain and in CSF of mice and rats, respectively, while plasma A β 42 is lowered by > 90% in both species. These *in vivo* results are relevant since the CSF A β 42 biomarker has been and is currently being used in clinical trials in order to assess target engagement (Fleisher et al., 2008; Coric et al., 2012; Toyn et al., 2016; Soares et al., 2016).

BPN-15606 fulfills practically all of our lead identification profile criteria for a clinical candidate. Since the discovery of this pyridazine scaffold, further optimization efforts have been undertaken through synthesis of an additional 134 pyridazine GSMs, all of which are close structural analogs of BPN-15606 (Wagner et al., 2016) with the goal of identifying one or more backup compounds to BPN-15606 that are free of any significant liabilities. Furthermore, as we pursue a therapy for a challenging disorder such as AD, establishing a series of credible backup lead molecules to BPN-15606 is critically important.

We have previously shown that attenuation of A β 42 levels over an extended period of time (7 months) dramatically reduces the number of amyloid plaques in Tg2576 transgenic mice (Kounnas et al., 2010). These data were generated following chronic oral treatment with 50 mg/kg/day of an aminothiazole-bridged aromatic GSM, or AGSM, similar in structure and function to the GSMs that we have been optimizing and characterizing over the past four years. The AGSMs act through a mechanism similar to our new lead GSM, by potently inhibiting A β 42 and A β 40 while potentiating A β 38 and A β 37.

Biochemical and Pathological Efficacy in Rodents and a 3D Human Neural Cell Model. In this study we have shown that a potent novel pyridazine C-ring-containing GSM (BPN-15606) significantly lowered A β 42 levels in plasma and brain/CSF of mice and rats at doses 10-fold lower than doses

previously required for AGSMs (Fig. 5; Kounnas et al., 2010). In addition, BPN-15606 demonstrated dose-dependent efficacy in both mice and rats, as well as dose-dependent exposures at doses ranging from 10-50 mg/kg in mice and at doses ranging from 5-50 mg/kg in rats (Supplemental Tables 6 and 7). Importantly, the concentrations of free drug achieved in the brain at doses as low as 5-10 mg/kg in rats and mice, respectively, are still almost 2-fold above the *in vitro* IC₅₀ for lowering A β 42. The pharmacokinetic parameters of BPN-15606 in mouse and rat (Supplemental Tables 3 and 4) support the significant dose-dependent efficacies and dose-dependent exposures achieved in the two independent efficacy studies.

In the chronic (6 month) efficacy study in the PSAPP transgenic mice, treatment with BPN-15606 at a dose of 10 mg/kg/day starting with 3 month old PSAPP mice, which presumably already had significant amyloid deposition, at 9 months of age there was resulted in a substantial reduction in the amount of Thiofavin S positive neuritic plaques in the BPN-15606 treated PSAPP mice compared to the vehicle treated 9 month old PSAPP mice (Fig. 7). These data demonstrating mitigation of neuropathology were consistent with the ability of BPN-15606 to substantially reduce the levels of insoluble A β 42 as well as insoluble total tau and pThr181 tau in the 3D human neural cell culture model of AD, suggesting that BPN-15606 reduced p-tau pathology and A β 42 accumulation (Fig. 8).

Repeat Dose Toxicity. In addition to potency, BPN-15606 has acceptable PK/PD properties including bioavailability, half-life and clearance (Supplemental Tables 3, 4 and 5). This PK/PD profile is reflected in the ability compound to sustain significant lowering of A β 42 for \geq 24 hours in mouse brain after a single dose (Fig. 6). BPN-15606 has undergone extensive preclinical study including *in vitro* ADMET and metabolite profiling in five species (Supplemental Tables 1 and 2), which confirms the absence of any unique human metabolites. Additionally, this compound demonstrated a no observed effect level (NOEL) in the rat dose range-finding and toxicokinetic study of \geq 30 mg/kg after 7 days of dosing (Supplemental Table 9) and a no observed adverse effect level (NOAEL) of 50 mg/kg in the rat efficacy study after 9 days dosing where significant efficacy was achieved at the lowest dose tested of 5 mg/kg

(Fig. 5), suggesting a ≥ 10 -fold safety margin based on dose. In this same rat study, the maximum tolerated dose (MTD) was estimated at 100 mg/kg. BPN-15606 demonstrated an NOAEL of 30 mg/kg after a single dose in cynomolgus macaques, based on emesis noted at higher doses (Fig. 10 and Supplemental Table 9). In the NHP dose-range finding and toxicokinetic study, a single dose escalation phase was used to determine the MTD (300 mg/kg) which was followed by a repeat dose phase of 6 days at the MTD. Emesis limited treatment duration to 6 days which was accompanied by a weight loss of up to 10.5% relative to Day 1, which was likely related to emesis and reduced food consumption. There were no gross findings at necropsy and histopathologic findings were limited to mild to moderate proximal tubular necrosis with subacute inflammation in two of two males and one of two females. In the liver, the histopathologic findings were reported as “less convincing” but included minimal sinusoidal leukocytosis in two of two males and moderate focal fatty infiltration in one of two females. As repeated oral administration of 300 mg/kg BPN-15606 to cynomolgus monkeys was associated with dose-limiting adverse effects after 6 days, doses of 100, 60, 30 and 10 mg/kg are planned for the IND-enabling 28-day GLP study.

Further Preclinical and Clinical Development. To date no GSM has been tested in Alzheimer’s patients. In a series of excellent studies recently published by Bristol-Myers Squibb (Toyn et al., 2016; Soares et al., 2016) the GSM, BMS-932481, demonstrated robust translation across several preclinical species as well as human subjects. Unfortunately, in repeated oral dosing studies in humans, BMS-932481 elicited transient elevations in plasma concentrations of enzymes associated with hepatic toxicity which precluded robust lowering A β peptides through oral dosing, thus terminating further clinical development of this once promising GSM. The authors suggested that cause of the elevation in hepatic enzymes by BMS-932481 was unlikely mechanism-based and possibly the result of the high degree of nonspecific protein binding which demanded plasma exposures in the micromolar range in order to achieve significant modulation of γ -secretase in brain (Toyn et al., 2016). Recently another GSM (FRM-36143) was published by groups from McGill University and FORUM pharmaceuticals which showed

reasonable *in vitro* ($EC_{50}=35$ nM) and *in vivo* potencies (maximum 58% reduction of A β 42 in rat CSF at a dose of 30 mg/kg); however, the lack of any reported repeated exposure toxicity and safety data make a prediction on the suitability of this compound for future clinical studies uncertain at this point (Blain et al., 2016).

Decisions on the future of BPN-15606 await the results of the FDA reviewed planned 28-day GLP IND-enabling studies, although based on the summation of the results of the studies presented on BPN-15606 herein, in combination with traditional allometric scaling algorithms, we project that slightly less than micromolar plasma exposures will be necessary to elicit significant lowering of A β 42 in human brain and should require much lower doses than those reported for BMS-932481 by Toyn et al., 2016 and Soares et al., 2016. Hopefully, BPN-15606 will ultimately be granted the opportunity to be tested in the appropriate human subjects and patients.

Acknowledgements

The authors would like to thank Rong Wang of Icahn Institute Department of Genetics and Genomic Sciences for assisting with the *in vitro* mass spectrometry analysis of amyloid beta. The authors would also like to acknowledge SRI International for their support in conducting selected pharmacokinetic and repeat dose toxicological studies. The authors would like to also thank Albany Molecular Research, Inc. for their support in conducting the *in vitro* ADMET screening. The authors would like to acknowledge the contributions of Charles Cywin of the National Institute of Neurological Disorders and Stroke and Lorenzo Refolo of the National Institute on Aging for their guidance and insights throughout of the course of this research program.

JPET #240861

Authorship Contributions

Participated in research design: Wagner, Ryneerson, Duddy, Johnson, Lin, Mobley, Rissman, and Tanzi.

Conducted experiments: Zhang, Nguyen, Becker, Vo, Masliah, Monte, Klee, Echmalian, Xia, and Quinti.

Contributed new reagents or analytic tools: Wagner, Ryneerson, Kim, and Tanzi.

Performed data analysis: Wagner, Ryneerson, Duddy, Johnson, Lin, Mobley, Rissman, Kim, and Tanzi.

Wrote or contributed to the writing of the manuscript: Wagner, Ryneerson, and Duddy.

References

- Blain JF, Bursavich MG, Freeman EA, Hrdlicka LA, Hodgdon HE, Chen T, Costa DE, Harrison BA, Kapadnis S, Murphy DA, Nolan S, Tu Z, Tang C, Burnett DA, Patzke H, and Koenig G (2016) Characterization of FRM-36143 as a new δ -secretase modulator for the potential treatment of familial Alzheimer's disease. *Alzheimer's Res Ther.* **8**: 34.
- Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE, and Kim DY (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* **515**: 274-278.
- Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, and Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. *J Neurosci.* **23**: 8844-8853.
- Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, and Berman RM (2012) Safety and tolerability of the γ -secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. *Arch Neurol.* **69**: 1430-1440.
- Crump CJ, Johnson DS, and Li YM (2013) Development and mechanism of δ -secretase modulators for Alzheimer's disease. *Biochemistry* **52**: 3197-3216.
- Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R, and Semagacestat Study Group (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N Engl J Med* **369**: 341-350.
- Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, and Thal LJ (2008) Phase II safety trial targeting

- amyloid beta production with a γ -secretase inhibitor in Alzheimer's disease. *Arch Neurol.* **65**: 1031-1038.
- Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, and AN1792 (QS-21)-201 Study Team (2005) Clinical effects of A β immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* **64**: 1553-1562.
- Golde TE, Schneider LS, and Koo EH (2011) Anti-A β therapeutics in Alzheimer's disease: The need for a paradigm shift. *Neuron* **69**: 203-213.
- Haapasalo A and Kovacs DM (2011) The many substrates of presenilin/ δ -secretase. *J Alzheimer's Dis.* **25**: 3-28.
- Hardy JA and Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. *Science* **256**: 184-185.
- Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, and Ihara Y (1994) Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: Evidence that an initially deposited species is A β 42(43). *Neuron* **13**: 45-53.
- Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, and Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific γ -secretase. *Hum Mol Genet.* **13**: 159-170.
- Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynt D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE and Wagner SL (2010) Modulation of γ -secretase in vivo reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. *Neuron* **67**: 769-780.
- Kumar-Singh S, Theuns J, Van Broek B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, and Van Broeckhoven C (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A β 42 and decreased A β 40. *Hum. Mutat.* **27**: 686-695.

- Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sjögren M, Margolin R, Chen X, Farlow MR, Dean RA, and Waring JF (2015) An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- β concentrations collected by lumbar puncture and indwelling lumbar catheter. *Alzheimer's Res Ther.* **7**: 53.
- Miles LA, Crespi GA, Doughty L, and Parker MW (2013) Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. *Sci Rep.* **3**: 1302.
- Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, Demattos RB, Racke MM, Zetterberg H, May PC, Blennow K (2014) β -site amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces A β 5-X peptides through alternative amyloid precursor protein cleavage. *Alzheimer's Res Ther.* **6**: 75.
- Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, and Bateman RJ (2013) Increased in vivo amyloid- β 42 production, exchange, and loss in presenilin mutation carriers. *Sci Transl Med.* **5**: 189.
- Qiu C, Kivipelto M, and von Strauss E (2009) Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. *Dialogues Clin Neurosci.* **11**: 111-128.
- Sabbagh M and Cummings J (2011) Progressive cholinergic decline in Alzheimer's disease: Consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. *BMC Neurol.* **11**: 21.
- Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, and Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzimab in mild-to-moderate Alzheimer's disease. *N Engl J Med* **370**: 322-333.
- Schmid W (1975) The micronucleus test. *Mutat Res.* **31**: 9-15.

- Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C Nitsch RM, and Sandrock A (2016) The antibody aducanumab reduces A β plaques in Alzheimer’s disease. *Nature* **537**: 50-56.
- Soares HD, Gasior M, Toyn JH, Wang JS, Hong Q, Berisha F, Furlong MT, Raybon J, Lentz KA, Sweeney F, Zheng N, Akinsanya B, Berman RM, Thompson LA, Olson RE, Morrison J, Drexler DM, Macor JE, Albright CF, Ahljanian MK, and Tarif MA (2016) The gamma-secretase modulator, BMS-932481, modulates A β peptides in the plasma and CSF of healthy volunteers. *J Pharmacol Exp Ther.* **358**: 138-150.
- Tanzi RE and Bertram L (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. *Cell* **120**: 545-555.
- Toyn JH and Ahljanian MK (2014) Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid- β . *Alzheimer’s Res Ther.* **6**: 14.
- Toyn JH, Boy KM, Raybon J, Meredith JE, Robertson AS, Guss V, Hoque N, Sweeny F, Zhuo X, Clarke W, Snow K, Denton RR, Zuev D, Thompson LA, Morrison J, Grace J, Berisha F, Furlong M, Wang JS, Lentz KA, Padmanabha R, Cook L, Wei C, Drexler DM, Macor JE, Albright CF, Gasior M, Olson RE, Hong Q, Soares HD, AbuTarif M, and Ahljanian MK (2016) Robust translation of γ -secretase modulator pharmacology across preclinical species and human subjects. *J Pharmacol Exp Ther* **358**: 125-137.
- Wagner S L, Mobley WC, Tanzi RE, Johnson G, Buckle RN, Mayhew NJ, Herr R. J, and Rynearson KD (2016) Potent gamma-secretase modulators. International patent publication WO2016/070107. Assignee: The Regents of the University of California and The General Hospital Corporation.
- Wagner SL, Tanzi RE, Mobley WC, and Galasko D (2013) Potential use of γ -secretase modulators in the treatment of Alzheimer’s disease. *Arch Neurol.* **69**: 1255-1258.

- Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Ryneerson KD, Wang R, Sisodia SS, Mobley WC and Tanzi RE (2014) Soluble γ -secretase modulators selectively inhibit production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. *Biochemistry* **53**: 702-713.
- Wakabayashi T and De Strooper B (2008) Presenilins: Members of the γ -secretase quartets, but part time soloists too. *J. Physiol.* **23**: 194-204.
- Zhang C, Kuo CC, Moghadam SH, Monte L, Campbell SN, Rice KC, Sawchenko PE, Masliah E, Rissman RA (2016) Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. *Alzheimer's Dement.* **12**: 527-537.

Footnotes

This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant U01-NS074501] and the Cure Alzheimer's Fund (CAF).

Drs. Wagner and Tanzi are shareholders and cofounders of a privately held company (Neurogenetic Pharmaceuticals, Inc.) that holds rights to a GSM currently in clinical development.

Figure Legends

Fig. 1. Chemical structure of BPN-15606.

Fig. 2. Concentration-response curves of BPN-15606 using SHSY5Y-APP cell-based MSD A β triplex screening assay.

Fig. 3. MALDI-TOF mass spectrum data of anti-A β 17-24 mAb (4G8) immunoprecipitates.

Fig. 4. Incubation of BPN-15606 (lanes 1-6) with H4-APP751 neuroglioma cells transfected with the Myc-tagged Notch (N Δ E) construct does not inhibit Notch proteolysis. Alternatively, incubation with δ -secretase inhibitor DAPT (lanes 7-10) potently inhibits Notch proteolysis.

Fig. 5. Levels of A β 42 (TOP) and A β 40 (BOTTOM) in plasma, brain or CSF following daily oral administration of either vehicle or BPN-15606. (A) A β peptides of male C57BL/6J mice (n = 10/dose) were measured in plasma and brain following a 7-day oral treatment course. (B) A β peptides of male Sprague Dawley rats (n = 14/dose) were measured in plasma and CSF following a 9-day treatment course. A β peptide levels were determined using Meso Scale Sector 6000 Multiplex assays.

Fig. 6. Levels of A β 42 (TOP) and A β 40 (BOTTOM) in plasma and brain or following single oral administration of either vehicle or BPN-15606. C57Bl6 mice (n = 5/time point) were dosed with 25 mg/kg of BPN-15606 or vehicle by oral gavage. Animals were then sacrificed at the indicated time point (0.5-24 hr) and the levels of A β 42 and A β 40 peptides were quantified using Meso Scale Sector 6000 Multiplex assays.

Fig. 7. Representative coronal sections of Thioflavin S stained images. Three month-old PSAPP mice were treated with BPN-15606 (10 mg/kg/day) or vehicle via laced chow for 6 months. Gray scale images

represent PSAPP mice at nine months of age. (A) Representative coronal section of age-matched wild-type negative control littermates. (B) Representative coronal section of vehicle-treated PSAPP mice. (C) Representative coronal section of BPN-15606-treated PSAPP mice. A β accumulation in Thioflavin S stained coronal sections was quantified using densitometry in nine month-old PSAPP mice chronically treated for six months. BPN-15606-treated cohort had significantly reduced accumulation of A β plaques in both the hippocampus (D) and cortex (E). n=10 per group. *: p<0.05. **: p<0.005. ***: p<0.0005.

Fig. 8. The impact of BPN-15606 on soluble and insoluble A β 40/ A β 42/ A β 38 and p-tau/total-tau levels in 3D human neural cell culture model of AD. The AD ReN cells (HReN-mGAP30) were 3D-differentiated for a total of 7 weeks while the 70 nM BPN-15606 and DMSO vehicle controls were treated for the last 4 weeks. (A) Relative levels of A β 40, A β 42 and A β 38 in soluble (media) fractions. BPN-15606 treatment dramatically decreased A β 42, A β 40 levels, as well as A β 42/40 ratio and increased A β 38 levels. (B) Relative levels of A β 40 and A β 42 in insoluble (5M GuHCl-soluble) fractions in the 3D-cultured cells with or without BPN-15606 treatment. (C) Relative levels of insoluble total and pThr181 tau. (D) The 1-week old treated media were analyzed by the Cytotox cell death LDH assay. BPN-15606 treatments did not induce any significant toxicity (n \geq 4 per each sample). Student t-test; *: p<0.05; **: p<0.01; ***: p<0.001.

Fig. 9. Plasma concentrations of BPN-15606 in male Sprague Dawley rats on Day 1 and Day 7. The test article (BPN-15606) was administered by oral gavage daily for 7 days. All animals in the 300 mg/kg group were either found dead or euthanized on Day 3 or 4.

Fig. 10. Design of NHP dose range-finding study. A dose escalation phase was used to determine the maximum tolerated dose (MTD) which was followed by a seven day repeat dose phase at the MTD. Toxicokinetic time points: Pre-dose, 1, 2, 4 (T_{max}), 8, and 24 hr.

^a Estimated based on clinical signs and clinical pathology in dose escalation.


^b Interval between doses was flexible and based on response/tolerance.

Fig. 11. Plasma concentrations of BPN-15606 in male and female Cynomolgus macaques on Days 1 and 6 of the repeated dose toxicology study. All pre-dose plasma samples collected on Day 6 contained measurable concentrations of BPN-15606. Each data point represents the mean \pm SD of n = 4 monkeys (2 males and 2 females).

JPET #240861


Figures

FIGURE 1




JPET #240861

FIGURE 2




JPET #240861

FIGURE 3




JPET #240861

FIGURE 4




JPET #240861

FIGURE 5




JPET #240861

FIGURE 6




JPET #240861

FIGURE 7




JPET #240861

FIGURE 8




JPET #240861

FIGURE 9



JPET #240861

FIGURE 10



JPET #240861

FIGURE 11

